StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
NASDAQ GLMD opened at $7.33 on Monday. Galmed Pharmaceuticals has a 52-week low of $2.73 and a 52-week high of $23.80. The company has a fifty day moving average of $4.37 and a 200-day moving average of $4.27. The company has a market capitalization of $36.98 million, a P/E ratio of -3.05 and a beta of 0.67.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- What is a Stock Market Index and How Do You Use Them?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What is the S&P/TSX Index?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Where to Find Earnings Call Transcripts
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
